PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are highly heterogeneous myeloid malignancies where few effective targeted therapies are available. While venetoclax has significantly advanced the treatment landscape, therapeutic resistance remains a critical challenge. Consequently, patients with relapsed or refractory (R/R) AML/MDS face a profound unmet medical need for novel therapeutic options. PBSS1113 has demonstrated robust anti-leukemic activity in both in vitro and in vivo models, alongside an acceptable safety profile in a Phase I study. This Phase Ib/II trial will ev

Trial Details

NCT ID
NCT07761533
Phase
PHASE1 / PHASE2
Sponsor
Chaser Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • PBSS1113
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Age and Gender: Age ≥ 18 years at the time of signing the informed consent form, male or female.
  • Disease Status: Must meet one of the following diagnostic criteria:
  • Relapsed or refractory (R/R) acute myeloid leukemia (AML).
  • Newly diagnosed AML in patients who are ineligible for intensive induction chemotherapy (including primary AML or secondary AML arising from myelod…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →